Vical slashes staff after culling phase II antifungalUS biotech Vical is planning another round of job cuts after deciding to abandon its antifungal drug VL-2397, Share XVical slashes staff after culling phase II antifungalhttps://pharmaphorum.com/news/vical-staff-culling-phase-ii-antifungal/
